GLP-1 Medications and Gastroparesis: Understanding the Risk and What You Need to Know

If you've been following headlines about GLP-1 medications like semaglutide and tirzepatide, you've probably seen alarming stories about gastroparesis, sometimes called "stomach paralysis." These reports can be frightening, especially when you're considering or already taking these medications for weight loss or diabetes management. Let's separate fact from fear and look at what the research actually tells us about GLP-1s and gastroparesis risk.

What Is Gastroparesis?

Gastroparesis is a condition where your stomach takes too long to empty its contents into your small intestine. In a healthy digestive system, strong muscular contractions push food through your digestive tract. With gastroparesis, these contractions slow down or don't work properly, causing food to linger in your stomach much longer than it should.

Symptoms can include persistent nausea, vomiting (sometimes of undigested food eaten hours earlier), feeling full after just a few bites, bloating, abdominal pain, and heartburn. In severe cases, it can lead to nutritional deficiencies and unpredictable blood sugar levels.

True gastroparesis is typically diagnosed through specific tests like gastric emptying studies, where you eat food containing a small amount of radioactive material that doctors can track as it moves through your system.

How GLP-1 Medications Affect Digestion

Here's something important to understand: GLP-1 medications are designed to slow stomach emptying. This isn't a side effect—it's actually one of the ways these medications work.

When you take semaglutide or tirzepatide, the medication mimics a natural hormone that slows down how quickly food leaves your stomach. This helps you feel fuller longer, reduces appetite, and helps control blood sugar spikes after meals. For most people, this slowed digestion is temporary and reverses when the medication is stopped.

This intentional slowing of digestion is very different from gastroparesis, which is a chronic condition where the stomach doesn't empty properly even without medication.

What Does the Research Say About GLP-1s and Gastroparesis Risk?

The concern about gastroparesis and GLP-1 medications gained attention after a 2023 study suggested a possible link. However, it's crucial to understand what the research actually shows—and what it doesn't.

Large-scale studies have found that the absolute risk of developing gastroparesis while on GLP-1 medications remains quite low. The challenge is that many of the symptoms of normal GLP-1-related delayed gastric emptying (nausea, feeling full quickly, bloating) overlap with gastroparesis symptoms, which can lead to confusion and potentially over-diagnosis.

Most people who experience digestive symptoms on GLP-1 medications have temporary side effects that improve over time or with dose adjustments—not permanent gastroparesis. When people stop taking the medication, stomach emptying typically returns to normal within weeks.

It's also worth noting that people with obesity and type 2 diabetes—the populations most likely to use GLP-1 medications—already have higher rates of gastroparesis even without these medications. This makes it challenging to determine whether GLP-1s cause the condition or simply unmask an existing problem.

Who Might Be at Higher Risk?

While gastroparesis risk appears low overall, certain factors may increase your vulnerability:

• Pre-existing digestive disorders or history of gastroparesis symptoms
• Long-standing, poorly controlled diabetes (which can damage the vagus nerve that controls stomach muscles)
• Previous stomach or esophageal surgery
• Certain autoimmune conditions or neurological disorders
• Rapid dose escalation without allowing your body time to adjust

Gender Differences in Gastroparesis Risk

Women are significantly more likely to be diagnosed with gastroparesis than men, regardless of GLP-1 use. Researchers estimate that women account for about 80% of gastroparesis cases overall. The reasons aren't entirely clear, but may involve hormonal factors, differences in gastric anatomy, or a higher likelihood of autoimmune conditions that can affect digestion.

This doesn't mean women should avoid GLP-1 medications—the benefits often far outweigh the risks—but it does mean women should be particularly attentive to digestive symptoms and communicate openly with their healthcare providers.

Warning Signs to Watch For

Most people on GLP-1 medications experience some mild, temporary digestive changes. But certain symptoms warrant a conversation with your doctor:

• Persistent vomiting, especially of undigested food many hours after eating
• Inability to keep down liquids or medications
• Severe abdominal pain that doesn't improve
• Significant unintended weight loss beyond your target
• Symptoms that worsen over time rather than improving
• Feeling full after just one or two bites of food

If you experience these symptoms, don't panic, but do reach out to your healthcare provider. They can assess whether you're experiencing normal medication adjustment, need a dose change, or require further evaluation.

Reducing Your Risk

You can take several steps to minimize digestive complications while on GLP-1 therapy:

• Start low and go slow with dosing—don't rush the titration schedule
• Eat smaller, more frequent meals rather than large portions
• Choose foods that are easier to digest, especially in the first few weeks
• Avoid lying down immediately after eating
• Stay well-hydrated throughout the day
• Limit high-fat and high-fiber foods if you're experiencing symptoms
• Keep an open dialogue with your prescribing physician about any digestive changes

The Bottom Line

While the headlines about gastroparesis and GLP-1 medications sound scary, the actual risk of developing true, permanent gastroparesis appears to be low. Most digestive symptoms people experience are temporary side effects that improve with time and proper management.

That said, these medications do significantly slow stomach emptying, and that's not right for everyone. If you have pre-existing digestive issues or develop concerning symptoms, working closely with a knowledgeable healthcare provider is essential.

The key is informed decision-making. GLP-1 medications have helped millions of people achieve meaningful weight loss and better metabolic health. Understanding the real risks—not the exaggerated ones—helps you make the best choice for your individual situation.

From the Ozari Care Team

If you're experiencing persistent nausea or feeling uncomfortably full on your current GLP-1 dose, don't suffer in silence or stop abruptly. Often, temporarily reducing your dose or slowing your titration schedule can resolve these symptoms while still allowing you to benefit from treatment. We're here to adjust your therapy to what works for your body, not just follow a one-size-fits-all protocol.

At Ozari Health we offer compounded Semaglutide and Tirzepatide starting at $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

Medically reviewed by the Ozari Clinical Care Team, licensed physicians specializing in metabolic health and GLP-1 therapy. Last reviewed: April 26, 2026